As truncating PPM1D mutations frequently occur in therapy-induced AML and MDS [28, 29], we decided to explore the connection between truncating PPM1D mutations, exposure to genotoxic agents, and cancer development. This evidence concerns the gene PPM1D and myelodysplastic syndrome.